Regulatory clearance is the remaining gating factor, watch for FTC and European Commission final decisions on the remedy package. The sale processes for the two divestiture businesses will test market appetite and achievable multiples, which could affect pro forma leverage and capital allocation flexibility post-close.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Oct 21 $34.98entry
- T+1 · 26d ago +0.20%α +1.38% · $35.05
- T+5 · 20d ago −1.31%α −0.87% · $34.52
- T+18 · todayOpen
- T+20 · tomorrow Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AkzoNobel and Axalta are progressing toward closing their all-share merger of equals, now targeting Q1 2027. The companies have identified two required remedy divestitures, AkzoNobel's European Refinish business and Axalta's US Wood Coatings business, with combined revenue of less than EUR500 million, and have begun sale processes. Management reaffirmed the $600 million cost synergy target is unaffected by the remedies and emphasized front-loading procurement and SG&A synergies in year one post-close. The combined company will be named Axanzo N.V. (ticker AXZ) and an AkzoNobel EGM to approve the name and board appointments is set for November 30, 2026.
Key Financial Metrics
Key Facts
- Merger remains on track to close in Q1 2027, subject to remaining regulatory approvals and customary closing conditions.
- Two remedy divestitures identified: AkzoNobel's European Refinish business and Axalta's US Wood Coatings business, combined revenue less than EUR500 million.
- Management reaffirmed $600 million cost synergy target is independent of remedies and may be exceeded.
- Sale process for Axalta's Wood business (US) is ongoing; process for AkzoNobel's Refinish Europe has recently started.
- US requires remedy closing as condition precedent to merger; Europe requires a signed agreement with an acceptable buyer but not closing.
- Merger-related cash out for full year 2026 estimated at roughly EUR100 million, trending up in H2.
- AkzoNobel EGM scheduled for November 30, 2026 to approve combined company name (Axanzo N.V.) and appoint three non-executive directors.
- Combined company to be named Axanzo N.V., listed on Euronext Amsterdam and NYSE under ticker AXZ.
- Shareholders of both companies voted in favor of all merger resolutions on August 5, 2026.
Financial Impact
Remedy divestitures involve less than EUR500 million in combined revenue with ~19-20% profitability; $600 million cost synergy target reaffirmed; merger-related cash out ~EUR100 million in FY2026.
Risk Factors
- Regulatory approvals may be delayed or subject to additional conditions beyond the identified remedies.
- Remedy divestiture sale processes may yield lower-than-expected proceeds or fail to attract acceptable buyers, particularly for the European Refinish business where the process is just starting.
- Merger integration costs and cash outflows could exceed current estimates, pressuring near-term free cash flow.
- Execution risk in front-loading two-thirds of cost synergies within year one post-close.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0000950103-26-015958 |
| Document: 0000950103-26-015958-index-headers.html | 0000950103-26-015958 |
| Document: 0000950103-26-015958-index.html | 0000950103-26-015958 |
| Document: 0000950103-26-015958.txt | 0000950103-26-015958 |
Track record
44 reports on AXTA
5 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +16.39% at T+60 after the Jun 3, 2026 report. 6 of 10 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry price pending
- Nov 12, 20264d ago SC 13G Neutral 3/10 Entry $36.41 to $36.56 Now $36.56 +0.41% ▲ +0.41% +0.78% vs SPY
- Nov 12, 20264d ago 425 Neutral 4/10 Entry $36.41 to $36.56 Now $36.56 +0.41% ▲ +0.41% +0.78% vs SPY
- Nov 12, 20264d ago 425 Neutral 4/10 Entry $36.41 to $36.56 Now $36.56 +0.41% ▲ +0.41% +0.78% vs SPY
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $37.07 to $36.41 Now $36.56 −1.38% ▼ −1.78% −1.43% vs SPY
- Nov 6, 202610d ago 425 Neutral 5/10 Entry $37.53 to $37.38 Now $36.56 −2.58% ▼ −0.40% −0.03% vs SPY
- Nov 6, 202610d ago 425 Bullish 6/10 Entry $36.45 to $37.53 Now $36.56 +0.30% ▲ +2.96% +0.60% vs SPY
- Nov 6, 202610d ago Press Release Bullish 5/10 Entry $36.45 to $37.53 Now $36.56 +0.30% ▲ +2.96% +0.60% vs SPY
- Oct 29, 202618d ago 425 Bearish 4/10 Entry $34.07 to $35.84 Now $36.56 −7.31% ▼ −5.20% −5.67% vs SPY
- Oct 29, 202618d ago 425 Neutral 4/10 Entry $34.07 to $35.84 Now $36.56 +7.31% ▲ +5.20% +5.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers